Navigation Links
Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
Date:2/22/2011

VANCOUVER, British Columbia, Feb. 22, 2011 /PRNewswire/ -- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the IN3 West Investment in Innovation Conference on Thursday, February 24 at 11:05 AM PST. The conference is being held at the Venetian Hotel in Las Vegas.

Dr. Rewcastle will provide an overview of Enox's technology and its ability to embed nitric oxide into polymer medical devices rendering them antimicrobial. He will also review recently published independent data that shows that ionic silver coatings for medical devices are not as effective as hoped.

"There is a very significant clinical need for an effective non-antibiotic treatment to render medical devices antimicrobial," said Rewcastle. "Each year in the United States alone, hospital acquired infections kill hundreds of thousands of patients and cost the health care system tens of billions of dollars. Silver coatings were hoped to be an answer to increasing antibiotic but, based on recent publications, this does not appear to be the case. Our nitric oxide technology is uniquely positioned to answer this critical need of all healthcare systems worldwide."

"The IN3 West Conference is an ideal venue for Enox to present at," continued Rewcastle. "The participants consist of both venture capitalists and larger companies seeking to partner with emerging technologies. I am looking forward to the meeting and expect a very positive response."About Enox Biopharma Inc.Enox Biopharma, Inc. is an emerging biotechnology company with proprietary technology that embeds nitric oxide (NO) into polymer medical devices. The innate immune system uses NO to block microbial growth - embedding NO into medical devices makes them antimicrobial. Enox's technology is applicable to any indwelling polymer medical device including, but not limited to catheters, endotracheal tubes, tympanostomy tubes and cosmetic implants. With the current CMS non-coverage of certain nosocomial infections the financial burden of these infections has shifted to hospitals who are desperately seeking ways to reduce infection rates. By utilizing NO, part of the human body's innate immune system, Enox Biopharma is improving existing medical devices by making them antimicrobial.

Forward Looking Information

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements are based on management's good faith views and expectations when made. Forward-looking statements are inherently subject to known and unknown risks and uncertainties which, in the case of the company, include raising adequate capital to continue operations, technology and product development uncertainties, and competition. Actual financial results of the company may differ, perhaps materially, from those discussed in the forward-looking statements. The company is not obligated, and does not undertake, to update its forward-looking statements or comment on the differences that may develop between its statements and actual results. Readers are encouraged to refer to the recent public filings of the company to further ascertain the risks associated with the forward-looking statements. Readers are urged not to place undue reliance upon such statements.For more information, please contact:John C. Rewcastle, Ph.D., CEO orItamar David, CFOEnoxBiopharma, Inc.604.637.9744 phone888.224.7259 faxinfo@enoxbiopharma.comwww.enoxbiopharma.com
'/>"/>

SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
2. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
3. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
4. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
5. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
6. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
7. Plato BioPharma, Inc Appoints New Board Member
8. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
9. Lexicon to Present Research Results at American Chemical Society Meeting Regarding Target of LX1031 Drug Candidate
10. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
11. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/16/2019)... , ... November 15, 2019 , ... ... living with memory impairment, has announced the Best Memory Care Facilities in Columbus, ... experts, facility features and amenities. , According to the Alzheimer’s Association ...
(Date:11/16/2019)... ... November 15, 2019 , ... October 29 article ... any time when more than usual is being consumed – is best done near ... doing so, the sugars and acids found in candy are more likely to be ...
(Date:11/15/2019)... ... , ... JustCBD looks forward to working with Hope For The ... by the military families aboard Marine Corps Base Camp Lejeune, North Carolina. These families ... the past 13 years, Hope For The Warriors has been dedicated to serving those ...
Breaking Medicine Technology:
(Date:11/15/2019)... N.Y. (PRWEB) , ... November 15, 2019 , ... ... of over 100 employers in Newsday’s Top Long Island Workplaces for 2019. The ... , During the selection process, Newsday worked in partnership with Energage to ...
(Date:11/14/2019)... (PRWEB) , ... November 14, 2019 , ... ... treatments for cancers and other serious diseases, announced it will have 5 poster ... at the upcoming 24th Annual Society for Neuro-Oncology SNO Meeting in Phoenix, beginning ...
(Date:11/12/2019)... ... November 12, 2019 , ... ... individuals/organizations who have truly impacted those diagnosed with infertility. This year, Academy of ... Award for Achievement, presented at the Night of Hope Gala in New York ...
(Date:11/12/2019)... (PRWEB) , ... November 12, 2019 , ... ... most complete business management solution for physical therapy and rehabilitation operators throughout the ... engagement technology with customers in 102 countries, today announces a joint venture to ...
(Date:11/11/2019)... ... November 11, 2019 , ... Thermal Product Solutions, a ... Gruenberg Depyrogenation Sterilizers to the Pharmaceutical Industry. The units will be used ... 280°C with work chamber dimensions of 36” W x 36” D x 53” ...
Breaking Medicine News(10 mins):